Response to cell cycle-dependent cytostatic agents may be reduced by an arrest in the cell cycle, and targeting CD20 as well as BTK may lead to partial antagonization of each other's effects, providing a rationale for the lack of PFS improvement observed in CLL after adding rituximab to ibrutinib treatment (Burger et al., 2019). Here, BTK is linked to B-cell chronic lymphocytic leukemia.